Marlio Charles Mosseri Purchases 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri purchased 17,000 shares of the business's stock in a transaction dated Friday, December 13th. The shares were purchased at an average cost of $4.70 per share, with a total value of $79,900.00. Following the purchase, the insider now directly owns 2,612,000 shares in the company, valued at approximately $12,276,400. The trade was a 0.66 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Nuvectis Pharma Stock Performance

Nuvectis Pharma stock traded up $0.17 during midday trading on Monday, reaching $4.87. 95,527 shares of the company were exchanged, compared to its average volume of 116,605. The company has a market capitalization of $94.09 million, a price-to-earnings ratio of -4.20 and a beta of 0.20. The firm's 50-day simple moving average is $6.52 and its 200-day simple moving average is $6.55. Nuvectis Pharma, Inc. has a 1 year low of $4.52 and a 1 year high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same period in the previous year, the business earned ($0.37) earnings per share. On average, analysts forecast that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Nuvectis Pharma by 1.5% in the first quarter. Vanguard Group Inc. now owns 298,800 shares of the company's stock valued at $2,450,000 after purchasing an additional 4,517 shares during the period. Renaissance Technologies LLC grew its stake in Nuvectis Pharma by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company's stock valued at $472,000 after purchasing an additional 12,800 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Nuvectis Pharma during the 2nd quarter worth approximately $58,000. Iridian Asset Management LLC CT acquired a new position in shares of Nuvectis Pharma in the 3rd quarter valued at approximately $348,000. Finally, Nations Financial Group Inc. IA ADV purchased a new position in shares of Nuvectis Pharma during the 3rd quarter valued at approximately $63,000. 96.77% of the stock is owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.